The soluble guanylate cyclase stimulator riociguat and the soluble guanylate cyclase activator cinaciguat exert no direct effects on contractility and relaxation of cardiac myocytes from normal rats.

@article{Reinke2015TheSG,
  title={The soluble guanylate cyclase stimulator riociguat and the soluble guanylate cyclase activator cinaciguat exert no direct effects on contractility and relaxation of cardiac myocytes from normal rats.},
  author={Yvonne G Reinke and Stefan Gross and Lars G. Eckerle and Isabel Hertrich and M. Busch and Raila Busch and A. R. Riad and Bernhard H Rauch and J. Stasch and Marcus D{\"o}rr and Stephan Burkhart Felix},
  journal={European journal of pharmacology},
  year={2015},
  volume={767},
  pages={
          1-9
        }
}
In cardiovascular diseases, reduced responsiveness of soluble guanylate cyclase (sGC) to nitric oxide (NO) upon long-term application has led to the development of NO-independent sGC stimulators (heme-dependent) and sGC activators (heme-independent). Any direct inotropic or lusitropic effects of these compounds on isolated cardiac myocytes, however, remain to be elucidated. Here, we analyzed the dose-dependent effects of clinical relevant concentrations (10(-10)-10(-5) M) of the sGC activator… CONTINUE READING
BETA

References

Publications referenced by this paper.
SHOWING 1-10 OF 56 REFERENCES

Riociguat for the treatment of chronic thromboembolic pulmonary hypertension.

Hossein-Ardeschir Ghofrani, Andrea Maria D'armini, +10 authors Chen Wang
  • The New England journal of medicine
  • 2013
VIEW 2 EXCERPTS
HIGHLY INFLUENTIAL

Riociguat for the treatment of pulmonary arterial hypertension.

Hossein-Ardeschir Ghofrani, Nazzareno Galié, +9 authors Lewis J. Rubin
  • The New England journal of medicine
  • 2013
VIEW 2 EXCERPTS
HIGHLY INFLUENTIAL

Cyclic GMP-dependent signaling in cardiac myocytes.

  • Circulation journal : official journal of the Japanese Circulation Society
  • 2012
VIEW 6 EXCERPTS
HIGHLY INFLUENTIAL

Similar Papers

Loading similar papers…